Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECCS 50

Drug Profile

ECCS 50

Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Plus Therapeutics; Adipose-derived stem cells - Plus Therapeutics; ADRCs - Plus Therapeutics; Cytori Cell Therapy; ECCI-50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytori Therapeutics
  • Developer Aix-Marseille University; Assistance Publique - Hopitaux de Marseille; Nagoya University; Plus Therapeutics
  • Class Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma; Urinary incontinence
  • Clinical Phase Unknown Crohn's disease; Scars

Most Recent Events

  • 29 Jul 2019 Cytori Therapeutics is now called Plus Therapeutics
  • 07 Mar 2019 Nagoya University completes the phase III ADRESU trial for Urinary incontinence in Japan (Transurethral) (NCT02529865)
  • 05 Mar 2019 Cytori Therapeutics and Assistance Publique - Hopitaux de Marseille terminates the phase II scleradec2 trial in Scleroderma in France (NCT02558543)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top